{"id":555274,"date":"2026-04-18T12:00:00","date_gmt":"2026-04-18T10:00:00","guid":{"rendered":"https:\/\/medizinonline.com\/progress-assessments-based-on-current-long-term-and-real-world-data\/"},"modified":"2026-04-23T16:28:43","modified_gmt":"2026-04-23T14:28:43","slug":"progress-assessments-based-on-current-long-term-and-real-world-data","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/en\/progress-assessments-based-on-current-long-term-and-real-world-data\/","title":{"rendered":"Progress assessments based on current long-term and real-world data"},"content":{"rendered":"\n

A broad spectrum of systemic agents is now available for the treatment of moderate to severe psoriasis. At this year’s DDG congress “Dermatology compact + practical”, various studies were presented on the biologics ixekizumab, bimekizumab and risankizumab, as well as the tyrosine kinase 2 (TYK2) inhibitor deucravacitinib, among others, which focused on the evaluation of long-term therapeutic effects and treatment outcomes in everyday life. <\/strong><\/p>\n\n

Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich
Jetzt beitreten<\/a><\/div>
Already a member? Log in here<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"

A broad spectrum of systemic agents is now available for the treatment of moderate to severe psoriasis. At this year’s DDG congress “Dermatology compact + practical”, various studies were presented……... <\/p>\n

Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich
Jetzt beitreten<\/a><\/div>
Already a member? Log in here<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":555275,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Psoriasis: therapy with biologics and TYK-2-i","footnotes":""},"category":[11513,11340,11442,11480,11548,11503],"tags":[27074,12391,66164,12548,14032,26569,81433,91668,91667,91666],"powerkit_post_featured":[],"class_list":["post-555274","post","type-post","status-publish","format-standard","has-post-thumbnail","category-congress-reports","category-dermatology-and-venereology","category-pharmacology-and-toxicology","category-rheumatology","category-rx-en","category-studies","tag-bimekizumab-en","tag-biologics-en","tag-deucravacitinib-en","tag-ixekizumab-en","tag-psoriasis-en-2","tag-risankizumab-en","tag-therapeutic-effects","tag-treatment-results","tag-tyk-2-i","tag-tyrosine-kinase-2-tyk2-inhibitor","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-06-17 03:28:49","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":555271,"slug":"evaluations-de-levolution-a-laide-de-donnees-actuelles-a-long-terme-et-de-donnees-du-monde-reel","post_title":"\u00c9valuations de l'\u00e9volution \u00e0 l'aide de donn\u00e9es actuelles \u00e0 long terme et de donn\u00e9es du monde r\u00e9el","href":"https:\/\/medizinonline.com\/fr\/evaluations-de-levolution-a-laide-de-donnees-actuelles-a-long-terme-et-de-donnees-du-monde-reel\/"},"it_IT":{"locale":"it_IT","id":555268,"slug":"valutazioni-dei-progressi-basate-su-dati-attuali-a-lungo-termine-e-reali","post_title":"Valutazioni dei progressi basate su dati attuali a lungo termine e reali.","href":"https:\/\/medizinonline.com\/it\/valutazioni-dei-progressi-basate-su-dati-attuali-a-lungo-termine-e-reali\/"},"pt_PT":{"locale":"pt_PT","id":555265,"slug":"avaliacoes-de-progresso-baseadas-em-dados-actuais-de-longo-prazo-e-em-dados-do-mundo-real","post_title":"Avalia\u00e7\u00f5es de progresso baseadas em dados actuais de longo prazo e em dados do mundo real","href":"https:\/\/medizinonline.com\/pt-pt\/avaliacoes-de-progresso-baseadas-em-dados-actuais-de-longo-prazo-e-em-dados-do-mundo-real\/"},"es_ES":{"locale":"es_ES","id":555262,"slug":"evaluaciones-de-progreso-basadas-en-datos-actuales-a-largo-plazo-y-del-mundo-real","post_title":"Evaluaciones de progreso basadas en datos actuales a largo plazo y del mundo real","href":"https:\/\/medizinonline.com\/es\/evaluaciones-de-progreso-basadas-en-datos-actuales-a-largo-plazo-y-del-mundo-real\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/555274","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/comments?post=555274"}],"version-history":[{"count":1,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/555274\/revisions"}],"predecessor-version":[{"id":555276,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/555274\/revisions\/555276"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media\/555275"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media?parent=555274"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/category?post=555274"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/tags?post=555274"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/powerkit_post_featured?post=555274"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}